Semi-automated BVA-100 analyzer is designed to provide rapid direct measurement of a patient’s true blood volume.
Daxor said the FDA-approved BVA-100 analyzer, which is used in conjunction with a single use diagnostic kit, has the potential to transform therapy in various surgical and medical conditions.
Daxor president and chief executive officer Joseph Feldschuh said regulations issued by Medicare are being implemented in January 2013 which will penalize hospitals who readmit congestive heart failure patients in less than 30 days.
"We feel that this should provide a major incentive for hospitals to use the BVA-100 Blood Volume Analyzer to treat congestive heart failure patients," Feldschuh added.
